⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
uPAR-Targeting Bispecific T-Cell Engager (GFD-CD3) Senolytic
Current understanding
A GFD-CD3 bispecific T-cell engager redirects endogenous T cells against uPAR-expressing senescent cells, eliminating them and alleviating age-related pathologies in aged mice and non-human primates when dosing is titrated against serum aminotransferase activity as a hepatotoxicity biomarker [animal-model]. Positioned as a more dose-titratable alternative to uPAR-directed senolytic CAR-T cells, with safety-monitor-guided dosing as its distinguishing feature [mechanism-plausible]. No human efficacy or safety data yet.
Evidence log
- 2026-09-29 — uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor: cross-connection with car-t-senolytics: Both are immuno-senolytic cell-engaging modalities targeting senescent-cell surface antigens; the uPAR-targeting bispecific T-cell engager is an off-the-shelf, titratable (dose-adjustable via aminotransferase monitoring) alternative to engineered CAR-T senolytics, with the same mechanistic reliance on recruiting endogenous T cells to kill senescent targets. (novelty: 4)
- 2026-10-01 — uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.: cross-connection with car-t-senolytics: Both redirect T cells against uPAR+ senescent cells; the bispecific engager trades CAR-T’s durable engineered persistence for pharmacologic dose-titratability guided by aminotransferase monitoring. (novelty: 4)
Open questions
Related
Contributing findings
uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.
01-oct-2026
novelty 4
per-area 4
introduces